EXCLUSIVE: HeartSciences Announces Expansion of Artificial Intelligence Patent Portfolio
Heart Test Laboratories Inc d/b/a HeartSciences (NASDAQ: HSCS) has been issued a notice of patent allowance from the European Patent Office.
To date, HeartSciences has been granted or allowed 41 patents, including nine in the U.S. Issued international patents are across key countries including China, Brazil, Canada, India, South Korea, Mexico, and key European markets such as Germany, France, U.K., Italy, and the Netherlands.
The patent allowance covers quantification by an ECG of key echocardiographic measures of heart function using AI methods which have never been possible with a conventional ECG.
Andrew Simpson, CEO of HeartSciences, commented, "Millions of ECGs are performed worldwide every week, and the ECG is by far the most ubiquitous cardiac test. The addition of cardiac dysfunction detection to the ECG is expected to provide significant benefits to healthcare providers and health systems around the world.
"Given the huge market opportunity, protection of our intellectual property and patents in major markets is core to the Company as it provides intrinsic value to HeartSciences and would be expected to be a source of major competitive advantage as we move toward commercialization," Simpson added.
Price Action: HSCS shares closed at $0.77 on Wednesday.
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article EXCLUSIVE: HeartSciences Announces Expansion of Artificial Intelligence Patent Portfolio originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
